Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.12B | 940.20M | 747.72M | 801.22M | 702.80M | 498.83M |
Gross Profit | 526.37M | 489.57M | 367.69M | 412.99M | 376.21M | 260.52M |
EBITDA | -177.66M | -99.13M | -194.66M | -72.31M | 36.50M | -13.03M |
Net Income | -205.45M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M |
Balance Sheet | ||||||
Total Assets | 875.74M | 967.66M | 952.66M | 1.05B | 905.14M | 716.41M |
Cash, Cash Equivalents and Short-Term Investments | 315.36M | 438.33M | 467.91M | 616.90M | 623.81M | 484.94M |
Total Debt | 449.01M | 473.56M | 415.67M | 419.88M | 314.67M | 228.32M |
Total Liabilities | 742.45M | 704.56M | 639.03M | 612.84M | 472.02M | 350.11M |
Stockholders Equity | 133.28M | 263.10M | 313.63M | 439.95M | 433.11M | 366.31M |
Cash Flow | ||||||
Free Cash Flow | -54.16M | 4.99M | -83.41M | 7.51M | 87.85M | -7.63M |
Operating Cash Flow | 9.72M | 24.23M | -31.81M | 50.46M | 111.36M | 24.67M |
Investing Cash Flow | 52.43M | -23.48M | -85.74M | 33.17M | -186.88M | -296.06M |
Financing Cash Flow | -46.62M | 8.37M | 4.11M | 16.88M | 51.93M | 314.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $23.93B | 103.44 | 19.18% | ― | 25.99% | -40.46% | |
73 Outperform | $1.62B | 24.36 | 19.29% | ― | 40.98% | 34.80% | |
69 Neutral | $1.28B | 17.74 | 4.76% | ― | -0.61% | ― | |
68 Neutral | $29.54B | 52.74 | 22.83% | ― | 9.30% | -14.95% | |
61 Neutral | $3.08B | 30.62 | -17.87% | ― | 8.57% | -1154.64% | |
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% | |
49 Neutral | $845.29M | ― | -111.91% | ― | 25.84% | -47.67% |
On August 6, 2025, Tandem Diabetes Care received FDA clearance for its SteadiSet infusion set, designed for up to seven days of insulin delivery for type 1 diabetes patients. The company plans to launch SteadiSet as a standalone product and as part of its future Tandem Mobi tubeless system, with a focus on scaling up manufacturing and pre-commercial activities in the coming quarters.
On May 21, 2025, Tandem Diabetes Care, Inc. and Roche entities settled patent disputes related to insulin delivery systems, agreeing to terminate pending actions and granting each other non-exclusive licenses for ten years. Additionally, Tandem held its virtual Annual Meeting of Stockholders on the same day, where eight directors were elected, executive compensation was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025.